Drugs / JYP0061
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06137911 | Sep 2021 → Nov 2022 | — | Guangzhou JOYO Pharma Co., Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06158490 | Dec 2023 → Feb 2026 overdue | atopic eczema | Guangzhou JOYO Pharma Co., Ltd | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06697535 | May 2023 → Feb 2026 overdue | neuromyelitis optica | Guangzhou JOYO Pharma Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JYP0061 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06697535 ↗ |
| Route | Oral | “JYP0061 orally administered” NCT06137911 ↗ |